Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Technology Stocks & Market Talk With Don Wolanchuk -- Ignore unavailable to you. Want to Upgrade?

To: SGJ who wrote (165828)	1/4/2022 9:58:31 AM
From: w0z	3 Recommendations Recommended By isopatch roguedolphin Winfastorlose Read Replies (1) \| Respond to of 207728

Why won't they do the rest of the analysis and break it out by vaxx/vaxx free? I believe the problem is that there is no valid data for "vaxx/vaxx free". The point is (similar to the election data science analysis) that, statistically speaking, there is just something very wrong somewhere. “Just to give you an idea of how bad that is, a three-sigma or a one-in-200-year catastrophe would be 10%* increase over pre-pandemic,”* he said. “So 40% is just unheard of.” At this point, valid US data is either unavailable, suppressed or corrupted because of financial incentives to care providers. There is not even valid placebo data available because Pfizer (illegally) chose to allow placebo patients the option (which most took) to get their jab after only 2 months of the trial's initiation. If most of the side effect issues came later, there is no longer any basis for comparison. How convenient! The point of the insurance company is simply that something unexplained is causing an unprecedented and statistically unlikely change in death rates. What could have possibly happened in 2021 that is different? Hmmm... At this point our US data is so corrupted that we need to look to other countries for proper data analysis and conclusions. There is some hope that some EU countries (like Denmark) may be able to shed some light on the issue.